natgillin/translations-raw huggingface dataset:
PE/PI Event-Free Status, n (%)
Status bez PE/PI događaja, n (%)
Peak blood concentrations of robenacoxib are attained rapidly after subcutaneous injection in cats and dogs.
Vršne koncentracije robenakoksiba u krvi postižu se brzo nakon subkutane injekcije u mačaka i pasa.
Peak concentrations in serum are obtained within 3 (range 2 - 5) hours.
Vršne koncentracije u serumu postižu se unutar 3 sata (2 – 5 sati).
Peak concentrations in tissue cage fluid of 31.9 μg/ml were measured 2 days after administration.
Najviše vrijednosti koncentracija u tkivnoj tekućini od 31,9 g/ml izmjerene su 2 dana nakon primjene.
Peak concentrations were followed by a slow decline in systemic exposure with an apparent elimination half-life (t1/2) of 90 hours in plasma.
Nakon vršnih koncentracija uslijedio je spori pad sustavne izloženosti s prividnim poluvijekom uklanjanja (t1/2) od 90 sati u plazmi.
Peak concentrations were followed by a slow decline in systemic exposure with an apparent elimination half-life (t1/2) of approximately 91 hours in plasma.
Nakon vršnih koncentracija uslijedio je spori pad sustavne izloženosti s prividnim poluvijekom uklanjanja (t1/2) od približno 91 sata u plazmi.
Peak efavirenz plasma concentrations of 1.6 - 9.1 µM were attained by 5 hours following single oral doses of 100 mg to 1,600 mg administered to uninfected volunteers.
Vršne koncentracije efavirenza u plazmi od 1,6-9,1 µM dostignute su u zdravih dobrovoljaca do 5 sati nakon jednokratne primjene oralnih doza lijeka od 100 do 1600 mg.
Peak incidence of vaccine virus recovery occurred 1-2 days post-vaccination in clinical studies with Pandemic influenza vaccine H5N1 MedImmune.
U kliničkim ispitivanjima Pandemijskog cjepiva protiv influence H5N1 MedImmune, vršna prisutnost virusa cjepiva javila se 1 do 2 dana nakon cijepljenja.
Peak Inspiratory Flow Rate through the Spiromax Device
Brzina vršnog inspiracijskog protoka kroz inhalator Spiromax
Peak Inspiratory Flow Rate through theSpiromax Device
Brzina vršnog inspiratornog protoka kroz inhalator Spiromax
Peak levels of aztreonam are achieved at about one hour after i.m. administration.
Vršne razine aztreonama postižu se otprilike jedan sat nakon intramuskularne primjene.
Peak LFT (ALT or AST) elevations were generally higher in paediatric patients than in older patients.
Vršne vrijednosti na testovima jetrene funkcije (ALT ili AST) općenito su bile veće u pedijatrijskih bolesnika nego u starijih bolesnika.
Peak plasma concentration occurs at 1.5-2 hours after oral administration for irbesartan and 1-2.5 hours for hydrochlorothiazide.
Vršnu koncentraciju u plazmi nakon oralne primjene irbesartan postiže za 1,5-2 sata, a hidroklorotiazid za 1-2,5 sata.
Peak plasma concentrations (Cmax) of eslicarbazepine are attained at 2-3 hours post-dose and steady state plasma concentrations are attained after 4 to 5 days of once daily dosing, consistent with an effective half-life in the order of 20-24 hours.
Vršnu koncentraciju u plazmi (Cmax) eslikarbazepin dostiže 2-3 sata nakon doziranja, a koncentracija u plazmi u stanju dinamičke ravnoteže se postiže za 4 do 5 dana doziranjem jednom dnevno, u skladu sa efektivnim poluvijekom od 20-24 sata.
Peak plasma concentrations (Cmax) of eslicarbazepine are attained at 2-3 hours post-dose and steady state plasma concentrations are attained after 4 to 5 days of once daily dosing, consistent with an effective half-life in the order of 20-24 hours.
Vršnu koncentraciju u plazmi (Cmax) eslikarbazepin dostiže 2-3 sata nakon doziranja, a koncentracija u plazmi u stanju dinamičke ravnoteže se postiže za 4 do 5 dana doziranjem jednom dnevno, u skladu sa efektivnimpoluvijekom od 20-24 sata.
Peak plasma concentrations are attained at 1.5 - 2 hours after oral administration.
Vršne koncentracije u plazmi postižu se 1,5 do 2 sata nakon peroralne primjene.
Peak plasma concentrations are reached at 6 hours following administration in a postoperative period due to contributing factors such as anaesthesia, GI paresis, and surgical effects independent of the oral medicinal product formulation.
Vršne koncetracije u plazmi postižu se 6 sati nakon primjene u postoperativnom razdoblju, uslijed učinaka anestezije, gastrointestinalne pareze i samog zahvata, nezavisno od formulacije oralnog lijeka.
Peak plasma concentrations occur about 1 to 4 hours after an oral dose.
Do prve vršne koncentracije u plazmi dolazi oko 1 do 4 sata nakon oralne primjene.
Peak plasma concentrations of oseltamivir carboxylate decline with a half-life of 6 to 10 hours in most subjects.
Vršne koncentracije oseltamivirkarboksilata u oluvremenom od 6 do 10 sati.
Peak plasma levels (Cmax) of ceritinib are achieved approximately 4 to 6 hours after oral administration in patients.
Vršne razine ceritiniba u plazmi (Cmax) postižu se otprilike 4 do 6 sati nakon peroralne primjene u bolesnika.
Peak plasma levels of clomipramine and desmethylclomipramine are rapidly reached (approx.
Vršne plazmatske razine klomipramina i desmetilklomipramina dostižu se brzo (pribl.
Peak plasma tedizolid concentrations are achieved within approximately 3 hours after dosing after oral administration of Sivextro under fasted conditions.
Vršne koncentracije tedizolida u plazmi dostižu se približno 3 sata nakon doze lijeka Sivextro primijenjene peroralno natašte.
PEARL I was conducted in the US and Europe, M12- 536 in Japan.
Ispitivanje PEARL-I provodilo se u Americi i Europi a M12-563 u Japanu.
PEARL II, III, and IV
0,98 (0,93-1,04)
PEARL II, III, and IV
PEARL II, III i IV
Pearl Index
(0; 1,35)
Pearl Indices (see table):
Pearlovi indeksi (vidjeti tablicu):
PEARL- I– genotype 4, treatment-naïve or pegIFN + RBV experienced without cirrhosis
PEARL- I – ispitanici s infekcijom genotipom 4, prethodno neliječeni ili prethodno liječeni pegIFN i RBV bez ciroze
PEARL-II was a randomised, global multicentre, open-label trial conducted in 179 adults with chronic genotype 1b hepatitis C virus infection without cirrhosis who did not achieve SVR with prior treatment with pegIFN/RBV.
PEARL-III bilo je randomizirano, globalno, multicentrično, dvostruko slijepo, kontrolirano ispitivanje provedeno u 419 prethodno neliječenih odraslih ispitanika s kroničnom infekcijom virusom hepatitisa C genotipa 1b bez ciroze.
PEARL-II – genotype 1b, pegIFN+RBV-experienced, without cirrhosis
PEARL-II – ispitanici prethodno liječeni pegIFN i RBV s infekcijom genotipom 1b, bez ciroze
PEARL-II – genotype 1b, peginterferon+ribavirin-experienced
PEARL-III – prethodno neliječeni ispitanici s infekcijom genotipom 1b
PEARL-III – genotype 1b, treatment-naïve, without cirrhosis
PEARL-III – prethodno neliječeni ispitanici s infekcijom genotipom 1b, bez ciroze
PEARL-IV– genotype 1a, treatment-naïve
N=66 za ciljno mjesto NS5B.
PecFent
mikrograma
PecFent 100 micrograms/spray nasal spray solution Fentanyl
PecFent 100 mikrograma/potisak sprej za nos, otopina fentanil
PecFent 100 micrograms/spray nasal spray, solution
PecFent 100 mikrograma/potisak sprej za nos, otopina
PecFent 100 micrograms/spray nasal spray, solution PecFent 400 micrograms/spray nasal spray, solution Fentanyl
PecFent 100 mikrograma/potisak sprej za nos, otopina PecFent 400 mikrograma/potisak sprej za nos, otopina fentanil
PecFent 2 spray bottles in their child resistant containers are supplied in a carton containing 1 bottle.
Bočica lijeka PecFent sa 2 potiska i njezin spremnik siguran za djecu dobiva se u kutiji koja sadržava 1 bočicu.
PecFent 400 micrograms/spray nasal spray, solution
PecFent 400 mikrograma/potisak sprej za nos, otopina
PecFent can deliver 100, 200, 400 and 800 microgram doses as follows:
Primjenom PecFenta mogu se postići doze od 100, 200, 400 i 800 mikrograma, kako slijedi:
PecFent excipients
Pomoćne tvari lijeka PecFent
PecFent fentanyl
PecFent fentanil
PecFent is a nasal spray that contains the active substance fentanyl (100 and 400 micrograms per spray).
PecFent je sprej za nos koji sadrži djelatnu tvar fentanil (100 i 400 mikrograma po potisku spreja za nos).
PecFent is a ‘hybrid generic medicine’.
PecFent je „hibridni generički lijek”.
PecFent is for nasal use only.
PecFent je samo za primjenu za nos.
PecFent is not recommended for use in patients who have received monoamine oxidase (MAO) inhibitors within the previous 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.
PecFent se ne preporučuje za primjenu u bolesnika koji su primili inhibitore monoaminooksidaze (MAO) unutar proteklih 14 dana, jer je prijavljeno teško i nepredvidljivo potenciranje MAO inhibitora s opioidnim analgeticima.
PecFent is only to be used by spraying into your nostril.
PecFent treba upotrijebiti samo raspršivanjem u nosnicu.
PecFent is used in adults with cancer for a type of pain called ‘breakthrough’ pain.
PecFent koriste odrasli bolesnici s rakom za vrstu boli koja se naziva 'probijajuća bol'.
PecFent is used in patients who are already using opioids (a group of painkillers that includes morphine and fentanyl) to control long-term cancer pain.
PecFent primjenjuje se u bolesnika koji već koriste opioide (grupu analgetika koja uključuje morfij i fentanil) sa ciljem dugoročne kontrole boli uzrokovane rakom.
PecFent may interact with these medicines and you may experience mental status changes (e.g. agitation, hallucinations, coma), and other effects such as body temperature above 38°C, increase in heart rate, unstable blood pressure, and exaggeration of reflexes, muscular rigidity, lack of coordination and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea).
Može doći do interakcije PecFenta s tim lijekovima i mogli biste doživjeti promjene mentalnog statusa (npr. nemir, halucinacije, komu) i druge posljedice kao što su povišenje tjelesne temperature iznad 38°C, ubrzani otkucaji srca, nestabilan krvni tlak, prenaglašeni refleksi, mišićna ukočenost, nekoordiniranost i/ili probavni simptomi (npr. mučnina, povraćanje, proljev).
PecFent must not be used in patients who are not already taking opioids to maintain pain control, who have severe respiratory depression (inhibition of breathing) or who have severe obstructive lung conditions (diseases that severely impede breathing).
PecFent se ne smije koristiti u bolesnika koji već ne uzimaju opioide za održavanje kontrole boli, koji imaju ozbiljnu respiratornu depresiju ili koji imaju ozbiljno opstruktivno stanje pluća (bolesti koje ozbiljno otežavaju disanje).
PecFent nasal spray is only indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain
PecFent sprej za nos indiciran je samo za kontrolu probijajuće boli u odraslih koji već primaju terapiju održavanja opioidnim lijekovima za kroničnu karcinomsku bol.
PecFent nasal spray should be prescribed only by physicians experienced in the management of opioid therapy in cancer patients.
PecFent sprej za nos smiju propisivati samo liječnici s iskustvom u opioidnoj terapiji u bolesnika s karcinomom.
PecFent nasal spray should not be used to treat any other short-term pain or pain status
PecFent sprej za nos ne smije se koristiti za liječenje nekih drugih kratkotrajnih bolova ili bolnih stanja.
PecFent nasal spray should not be used to treat any other short-term pain or pain status.
PecFent sprej za nos ne smije se koristiti za liječenje nekih drugih kratkotrajnih bolova ili bolnih stanja.
PecFent should be administered with caution to patients with moderate or severe hepatic or renal impairment (see section 4.4).
PecFent se mora primjenjivati s oprezom u bolesnika s umjerenim ili teškim oštećenjem jetre ili bubrega (vidjeti dio 4.4).
PecFent should be titrated to an “effective” dose that provides adequate analgesia and minimises adverse reactions without causing undue (or intolerable) adverse reactions, for two consecutively treated episodes of BTP.
PecFent se mora titrirati na “djelotvornu” dozu, koja u dvije uzastopne epizode probijajuće boli pruža odgovarajuću analgeziju i umanji nuspojave bez uzrokovanja pretjeranih (ili nepodnošljivih) nuspojava.
PecFent should, therefore, be used with caution in patients with previous or pre-existing bradyarrhythmias.
Stoga u bolesnika s prijašnjim ili postojećim bradiaritmijama PecFent treba koristiti s oprezom.
PecFent that has passed the expiry date or is no longer required may still contain enough medicine to be harmful to other people, especially children.
PecFent kojem je istekao rok valjanosti ili Vam više nije potreban, može i dalje sadržavati dovoljno lijeka da našteti drugim ljudima, a osobito djeci.
PecFent was more effective than placebo in treating breakthrough cancer pain.
PecFent je bio djelotvorniji od placeba u liječenju probijajuće boli.
PecFent with food, drink and alcohol
PecFent s hranom, pićem i alkoholom
pecific lung disease with difficulties breathing (called interstitial lung disease)
pecifična bolest pluća s teškoćom pri disanju (zove se intersticijska bolest pluća)
pecific medicines for the treatment of bronchial asthma (β-sympathomimetics)
neki lijekovi za liječenje bronhalne astme (ß-simpatomimetici)
Ped ACR 30 Responses in the JIA study
Pedijatrijski odgovori ACR 30 u ispitivanju kod JIA
Pedea 5mg/ml solution for injection
Pedea 5 mg/ml otopina za injekciju ibuprofen
Pedea 5mg/ml solution for injection is a clear, colourless to slightly yellow solution.
Pedea 5 mg/ml otopina za injekciju je bistra, bezbojna do blago žuta otopina.
Pedea is used to treat ‘patent ductus arteriosus’ in newborn premature babies who were born six or more weeks too early (less than 34 weeks gestational age).
Pedea se koristi za liječenje „otvorenog arterijskog duktusa” u nedonoščadi rođene šest ili više tjedana prijevremeno (gestacijske dobi manje od 34 tjedna).
Pedea may be less effective in very premature babies less than 27 weeks of gestational age.
Pedea može biti manje učinkovita u djece koja su rođena prije 27 tjedana trudnoće.
Pedea may reduce the amount of urine your baby passes.
Pedea može smanjiti količinu mokraće Vašeg djeteta.
Pedea should be administered as a short infusion over 15 minutes, preferably undiluted.
Pedeu treba primjeniti u kratkotrajnoj infuziji tijekom 15 minuta, najbolje nerazrijeđenu.
Pedea should be carefully administered to your baby by the healthcare professional, to avoid damage to the skin and surrounding tissues.
Medicinski djelatnici trebaju Pedeu primjenjivati pažljivo Vašem djetetu da se izbjegne ozljeda kože i okolnog tkiva.
Pedea should not be given in the first 6 hours of life.
Pedea se ne smije primijeniti tijekom prvih 6 sati života.
Pedea will only be given to your baby in a special neonatal intensive care unit by qualified healthcare professional.
Pedeu će Vašem djetetu primjeniti iskusni medicinski djelatnici u specijalnoj jedinici intenzivne njege novorođenčadi.
Pediatric use (non approved): in children, clinically significant systemic toxicity has occurred at doses approved for the treatment of adult patients.
Pedijatrijska primjena (neodobrena): primjenom doza odobrenih za liječenje odraslih bolesnika, u djece je nastupila klinički značajna sistemska toksičnost.
peech disorder,
poremećaj govora,
peech problems
metnje govora
PEEL
ODVOJITE
Peel apart the foil and open the sachet.
Odlijepite foliju i otvorite vrećicu.
Peel back
Odlijepiti
Peel back paper at arrows
Ogulite crni papir kod strelica
Peel back the coloured tab (Figure 1).
Odlijepite obojanu naljepnicu (Slika 1).
Peel back the disposal label on the outside of the sachet.
S vanjske strane vrećice odvojite naljepnicu za odlaganje.
Peel back the foil from the capsule card to reveal one TOBI Podhaler capsule and remove it from the card.
Skinite foliju s kartice s kapsulama kako biste otkrili jednu TOBI Podhaler kapsulu i izvadili je iz kartice.
Peel back the foil of a single blister cell and press the back of the blister pocket to push the tablet out.
Odlijepite foliju s jedne jedinice blistera i pritisnite džepić blistera sa stražnje strane tako da tabletu izgurate van.
Peel back the lid from the clear plastic vial adapter package.
Povucite poklopac s prozirnog plastičnog pakiranja s nastavkom za bočicu.
Peel back the lid from the clear plastic vial adapter package.
Povucite pokrov s prozirnog plastičnog pakiranja s nastavkom za bočicu.
Peel back the paper cover from the vial adapter package.
Uklonite papirnati pokrov na pakiranju s nastavkom za bočicu.
Peel back the paper foil at the corner.
Odlijepite papirnatu foliju u kutu.
Peel back the paper lid completely.
Skinite u potpunosti papirnati pokrov.
Peel back the tab to get to the capsule - do not push the capsule through the blister since pushing the capsule through the package may break the capsule.
Odlijepite naljepnicu kako biste izvadili kapsulu - nemojte potiskivati kapsulu kroz blister jer se potiskivanjem kapsula može slomiti.
Peel here
Odlijepiti ovdje
Peel off one side of the release liner.
Odlijepite jednu stranu zaštitnog sloja.
Peel off paper backing slowly from vial adapter while keeping vial adapter in the plastic package.
Polako uklonite papirni pokrov s pakiranja nastavka za bočicu, no ostavite nastavak za bočicu u plastičnom pakiranju.
Peel off the backing liner to separate it from the adhesive pad.
Povucite zaštitnu foliju na poleđini kako biste je odvojili od ljepljive podloge.
Peel off the film from the syringe pack and remove the syringe.
Skinite film s pakiranja štrcaljke i izvadite štrcaljku.
Peel off the foil from the base of the needle cover.
Maknite foliju s baze pokrova za iglu.
Peel off the paper cover on the vial adapter plastic housing.
Odlijepite papirnati pokrov s plastičnog kućišta nastavka za bočicu.
Peel off the paper tab from the needle cover.
Odlijepite papirnati pokrov sa zatvarača igle.
Peel open the packaging of the syringe and safety needle to make it easier to pick up each item as you prepare for your injection.
Otvorite pakiranja štrcaljke i sigurnosne igle kako biste olakšali uzimanje svakog predmeta dok pripremate svoju injekciju.
Peel the backing away from the blister to open it - do not push the capsule through the foil.
Odlijepite foliju s blistera da biste ga otvorili - ne gurajte kapsulu kroz foliju.
Peel the blister backing to expose the tablet.
Odvojite poleđinu blistera kako biste otkrili tabletu.
Peel the clear package just far enough to expose the white plunger rod, but do not take the syringe out of the package.
Otvorite prozirno pakiranje tek toliko da bijeli klip štrcaljke bude dostupan, ali ne vadite štrcaljku iz pakiranja.
Peel the cover off the vial adapter package but do not take out the vial adapter.
Skinite pokrov s pakiranja nastavka za bočicu, ali nemojte vaditi nastavak.
Peel the lid off the syringe tray and, using aseptic technique, carefully remove the syringe.
Odlijepite poklopac s kasete sa štrcaljkom i, koristeći aseptičnu tehniku, pažljivo izvadite štrcaljku.
Peel the paper off of the tray.
Skinite pokrov s podloška.
Peel the tab from the outer needle cap.
Odlijepite zaštitnu naljepnicu s vanjskog zatvarača igle.
Peel-off
Odvojite
PEEL-OFF STICKERS FOR YOUR PERSONAL CALENDAR
NALJEPNICE ZA VAŠ OSOBNI KALENDAR
Peel.
Odvojite.
Peelable or non-peelable perforated unit dose blisters of aluminium/aluminium containing 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 tablets
Aluminij/aluminij perforirani blisteri s odvojivom folijom ili s neodvojivom folijom, djeljivi na jedinične doze sadrže 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ili 100x1 tableta
Peelable perforated blisters contain 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet.
Blisteri s odvojivom folijom djeljivi na jedinične doze koji sadržavaju 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ili 100x1 filmom obloženih tableta.
Peelable perforated blisters contain 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablets.
Perforirani blisteri s odvojivom folijom sadržavaju 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 filmom obloženih tableta.
Peelable perforated blisters of aluminium/aluminium containing 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 tablets
Aluminijskim perforiranim blisterima s odvojivom folijom, djeljivim na jedinične doze koji sadržavaju 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ili 100x1 tableta
Peeling (exfoliation)
Ljuštenje (eksfolijacija)
peeling skin
ljuštenje kože
peeling skin, increased skin sensitivity to sunlight, change in skin colour, increased sweating
ljuštenje kože, povećana osjetljivost kože na sunčevu svjetlost, promjena boje kože, pojačano znojenje
PEG-ASP (2500 IUnits/m2, IM): day 4
PEG-ASP (2500 IU/m2, i.m.): dan 4
PEG-ASP (2500 IUnits/m2, IM): day 4
PEG-ASP (2500 IU/m², i.m.): dan 4
Pegaptanib, the active substance of this medicine, inhibits the activity of the factor involved in the abnormal formation of new blood vessels in the eye, known as Vascular Endothelial Growth Factor165 (VEGF165).
Pegaptanib, djelatna tvar ovog lijeka, inhibira aktivnost faktora uključenog u abnormalno stvaranje novih krvnih žila u oku, poznatog kao vaskularni endotelni faktor165 rasta ( VEGF165).
Pegaspargase was well tolerated both in rats and dogs when administered intravenously in single dose up to 500 U/kg.
Pegaspargaza se dobro podnosila u štakora i pasa kada je primjenjivana intravenski u jednoj dozi do 500 U/kg.
PEGASUS study (History of Myocardial Infarction)
Studija PEGASUS (infarkt miokarda u anamnezi)
Pegasys
(N=88)
Pegasys
mikrograma i placebo
Pegasys
Pegasys Pegasys
Pegasys 135 micrograms solution for injection
Pegasys 135 mikrograma otopina za injekciju
Pegasys 135 micrograms solution for injection 3 years.
Pegasys 135 mikrograma otopina za injekciju 3 godine.
Pegasys 135 micrograms solution for injection EU/1/02/221/001
Pegasys 135 mikrograma otopina za injekciju EU/1/02/221/001
Pegasys 135 micrograms solution for injection in pre-filled pen
Pegasys 135 mikrograma otopina za injekciju u napunjenoj brizgalici
Pegasys 135 micrograms solution for injection in pre-filled pen EU/1/02/221/011
Pegasys 135 mikrograma otopina za injekciju u napunjenoj brizgalici EU/1/02/221/011
Pegasys 135 micrograms solution for injection in pre-filled pen Pegasys 180 micrograms solution for injection in pre-filled pen Peginterferon alfa-2a
Pegasys 135 mikrograma otopina za injekciju u napunjenoj brizgalici Pegasys 180 mikrograma otopina za injekciju u napunjenoj brizgalici peginterferon alfa-2a
Pegasys 135 micrograms solution for injection in pre-filled pen Peginterferon alfa-2a
Pegasys 135 mikrograma otopina za injekciju u napunjenoj brizgalici peginterferon alfa-2a
Pegasys 135 micrograms solution for injection in pre-filled syringe
Pegasys 135 mikrograma otopina za injekciju u napunjenoj štrcaljki
Pegasys 135 micrograms solution for injection in pre-filled syringe Peginterferon alfa-2a
Pegasys 135 mikrograma otopina za injekciju u napunjenoj štrcaljki peginterferon alfa-2a
Pegasys 135 micrograms solution for injection Pegasys 180 micrograms solution for injection
Pegasys 135 mikrograma otopina za injekciju Pegasys 180 mikrograma otopina za injekciju
Pegasys 135 micrograms solution for injection Pegasys 180 micrograms solution for injection Peginterferon alfa-2a
Pegasys 135 mikrograma otopina za injekciju Pegasys 180 mikrograma otopina za injekciju peginterferon alfa-2a
Pegasys 135 micrograms solution for injection Peginterferon alfa-2a
Pegasys 135 mikrograma otopina za injekciju peginterferon alfa-2a
Pegasys 180 mcg/week for 48 weeks
Pegasys 180 mikrograma/tjedan kroz 48 tjedana
Pegasys 180 mcg/week for 72 weeks
Pegasys 180 mikrograma/tjedan kroz 72 tjedna
Pegasys 180 micrograms solution for injection
Pegasys 180 mikrograma otopina za injekciju
Pegasys 180 micrograms solution for injection 4 years.
Pegasys 180 mikrograma otopina za injekciju 4 godine.
Pegasys 180 micrograms solution for injection EU/1/02/221/003
Pegasys 180 mikrograma otopina za injekciju EU/1/02/221/003
Pegasys 180 micrograms solution for injection in pre-filled pen
Pegasys 180 mikrograma otopina za injekciju u napunjenoj brizgalici
Pegasys 180 micrograms solution for injection in pre-filled pen Peginterferon alfa-2a
Pegasys 180 mikrograma otopina za injekciju u napunjenoj brizgalici peginterferon alfa-2a
Pegasys 180 micrograms solution for injection in pre-filled syringe
Pegasys 180 mikrograma otopina za injekciju u napunjenoj štrcaljki
Pegasys 180 micrograms solution for injection in pre-filled syringe EU/1/02/221/007
Pegasys 180 mikrograma otopina za injekciju u napunjenoj štrcaljki EU/1/02/221/007